Days went by and the girl's doctors never figured out what was wrong. When she was transferred to a different hospital, however, the issue was quickly identified and corrected.
Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.
Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.
